Bosh sahifaNVAX • SWX
add
Novavax Inc
Bozor kapitalizatsiyasi
1,55 mlrd USD
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 147,14 mln | 66,61% |
Joriy xarajat | 4,31 mln | -92,26% |
Sof foyda | 17,53 mln | 121,63% |
Sof foyda marjasi | 11,91 | 112,98% |
Har bir ulushga tushum | 0,11 | 121,33% |
EBITDA | 26,06 mln | 123,07% |
Amaldagi soliq stavkasi | 2,10% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 735,08 mln | -20,37% |
Jami aktivlari | 1,18 mlrd | -24,60% |
Jami passivlari | 1,30 mlrd | -40,29% |
Umumiy kapital | -127,75 mln | — |
Tarqatilgan aksiyalar | 162,94 mln | — |
Narxi/balansdagi bahosi | — | — |
Aktivlardan daromad | 4,44% | — |
Kapitaldan daromad | 42,77% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 17,53 mln | 121,63% |
Operatsiyalardan naqd pul | -39,48 mln | 77,20% |
Sarmoyadan naqd pul | 20,48 mln | -85,78% |
Moliyadan naqd pul | -6,60 mln | -92,99% |
Naqd pulning sof oʻzgarishi | -27,30 mln | 36,93% |
Boʻsh pul | -2,35 mln | 98,13% |
Haqida
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Tashkil etilgan
1987
Sayt
Xodimlar soni
749
